TOday’s Movers: Halozyme Therapeutics (NASDAQ:HALO) Stock Rating Maintained at BMO Capital; $15 Target Price Indicates -7.69 % Potential

September 17, 2017 - By test

 TOday’s Movers: Halozyme Therapeutics (NASDAQ:HALO) Stock Rating Maintained at BMO Capital; $15 Target Price Indicates  7.69 % Potential

Investors sentiment increased to 1.23 in 2016 Q4. Its up 0.27, from 0.96 in 2016Q3. It increased, as 20 investors sold Halozyme Therapeutics, Inc. shares while 44 reduced holdings. 26 funds opened positions while 53 raised stakes. 108.31 million shares or 4.02% more from 104.12 million shares in 2016Q3 were reported.

Franklin Res accumulated 1.03M shares. Msd Limited Partnership reported 965,000 shares. Great West Life Assurance Can accumulated 9,920 shares or 0% of the stock. Blackrock Institutional Tru Company Na reported 0% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Aqr Lc owns 0% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 15,546 shares. Amalgamated Comml Bank holds 0.01% in Halozyme Therapeutics, Inc. (NASDAQ:HALO) or 13,375 shares. 41,166 were reported by Horizon Kinetics Ltd Liability Com. Aperio Group Inc Limited Liability Corporation has invested 0% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Rhumbline Advisers accumulated 0% or 129,239 shares. Envestnet Asset holds 13 shares or 0% of its portfolio. Snyder Lp stated it has 1.29% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Blackrock Japan holds 0% in Halozyme Therapeutics, Inc. (NASDAQ:HALO) or 2,662 shares. Panagora Asset Mngmt owns 856,007 shares or 0.04% of their US portfolio. Northern Tru reported 1.38 million shares. Ifc Fl stated it has 0.08% in Halozyme Therapeutics, Inc. (NASDAQ:HALO).

Halozyme Therapeutics (NASDAQ:HALO) Rating Reaffirmed

Professional analysts at BMO Capital now has a $15 price target on Halozyme Therapeutics (NASDAQ:HALO). BMO Capital and their recent price target would indicate a potential downside of -7.69 % from the company’s previous close. The rating has been released in an analyst report on Friday morning.

Investors sentiment increased to 1.23 in 2016 Q4. Its up 0.27, from 0.96 in 2016Q3. It increased, as 20 investors sold Halozyme Therapeutics, Inc. shares while 44 reduced holdings. 26 funds opened positions while 53 raised stakes. 108.31 million shares or 4.02% more from 104.12 million shares in 2016Q3 were reported.

Franklin Res accumulated 1.03M shares. Msd Limited Partnership reported 965,000 shares. Great West Life Assurance Can accumulated 9,920 shares or 0% of the stock. Blackrock Institutional Tru Company Na reported 0% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Aqr Lc owns 0% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 15,546 shares. Amalgamated Comml Bank holds 0.01% in Halozyme Therapeutics, Inc. (NASDAQ:HALO) or 13,375 shares. 41,166 were reported by Horizon Kinetics Ltd Liability Com. Aperio Group Inc Limited Liability Corporation has invested 0% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Rhumbline Advisers accumulated 0% or 129,239 shares. Envestnet Asset holds 13 shares or 0% of its portfolio. Snyder Lp stated it has 1.29% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Blackrock Japan holds 0% in Halozyme Therapeutics, Inc. (NASDAQ:HALO) or 2,662 shares. Panagora Asset Mngmt owns 856,007 shares or 0.04% of their US portfolio. Northern Tru reported 1.38 million shares. Ifc Fl stated it has 0.08% in Halozyme Therapeutics, Inc. (NASDAQ:HALO).

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Ratings Coverage

Among 7 analysts covering Halozyme Therapeutics (NASDAQ:HALO), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Halozyme Therapeutics has $27 highest and $12 lowest target. $18.40’s average target is 13.23% above currents $16.25 stock price. Halozyme Therapeutics had 13 analyst reports since August 11, 2015 according to SRatingsIntel. Deutsche Bank initiated the shares of HALO in report on Thursday, November 3 with “Buy” rating. As per Friday, January 6, the company rating was downgraded by Citigroup. Piper Jaffray maintained the shares of HALO in report on Wednesday, August 9 with “Buy” rating. The stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9. The firm earned “Overweight” rating on Friday, September 16 by Piper Jaffray. The stock has “Buy” rating by Canaccord Genuity on Wednesday, July 26. The rating was initiated by Wells Fargo on Friday, December 4 with “Outperform”. As per Tuesday, August 11, the company rating was maintained by JMP Securities. The rating was maintained by Barclays Capital on Wednesday, February 24 with “Overweight”. The rating was maintained by Deutsche Bank with “Buy” on Friday, September 15.

The stock increased 1.69% or $0.27 on September 15, reaching $16.25. About 5.82M shares traded or 324.82% up from the average. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has risen 44.89% since September 17, 2016 and is uptrending. It has outperformed by 28.19% the S&P500.

Wall Street await Halozyme Therapeutics, Inc. (NASDAQ:HALO) to release earnings on November, 6. Analysts forecast EPS of $-0.26, down exactly $0.03 or 13.04 % from 2014’s $-0.23 EPS. After posting $-0.23 EPS for the previous quarter, Halozyme Therapeutics, Inc.’s analysts now forecast 13.04 % negative EPS growth.

Halozyme Therapeutics, Inc. is a biotechnology firm focused on developing and commercializing oncology therapies. The company has market cap of $2.27 billion. The Firm operates in research, development and commercialization of human enzymes and other drug candidates. It currently has negative earnings. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

More notable recent Halozyme Therapeutics, Inc. (NASDAQ:HALO) news were published by: Reuters.com which released: “Halozyme to license drug delivery tech to Roche, Bristol-Myers” on September 14, 2017, also Prnewswire.com with their article: “Halozyme Increases 2017 Financial Guidance” published on September 14, 2017, Prnewswire.com published: “Technical Insights on Biotech Stocks — Grifols, Halozyme Therapeutics …” on September 01, 2017. More interesting news about Halozyme Therapeutics, Inc. (NASDAQ:HALO) were released by: Fool.com and their article: “Here’s Why Halozyme Therapeutics, Inc. Is Soaring Today” published on September 14, 2017 as well as Marketwatch.com‘s news article titled: “Halozyme’s stock soars after Bristol-Myers license deal” with publication date: September 14, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.